Table 6.

Susceptibility of reverse‐engineered EV‐A71 strains to the AL‐385 prototype and 10.

Virus	EC50 [μM][a]
	AL‐385	10
EV‐A71 BrCr	0.28±0.01	0.33±0.07
VP1 S184T	1.99±0.10 (7.1)	0.4±0.03 (1.2)
VP1 P246S	4.71±0.18 (16.8)	0.36±0.02 (1.1)
VP1_S184T_P246S	8.93±0.53 (31.9)	0.35±0.05 (1)

[a] Averages and standard deviations were calculated from data obtained from three independent antiviral assays. Values in italics within the brackets indicate fold resistance.